Obesity

Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Diabetes Obes MetabPublished Systematic review and meta-analysis of randomised trials

Authors' conclusion

Bimagrumab effectively reversed adverse effects on body composition in obese individuals, resulting in significant fat reduction, increased skeletal muscle mass, and improved glycemic control

Study context

Population
Adults with obesity, insulin resistance or T2D
Participants
268 adults4 randomized controlled trials (RCTs)
Comparison
Bimagrumab vs placebo
Outcome
Efficacy on body composition and glucose parameters, and safety
Methodological detailsRoB 2 risk of bias assessment, Grades of Recommendation, Assessment, Development, and Evaluation (GRADE), Searched MEDLINE, PubMed, Embase, Cochrane Library on April 20, 2026
  • RoB 2 risk of bias assessment
  • GRADE
  • Searched MEDLINE, PubMed, Embase, Cochrane Library on April 20, 2026

Pooled result

As reported in the abstract

Each group vs placeboEstimate (95% CI)
Bimagrumab
MD (total weight) −4.85 kg(−6.82 to −2.88)
Bimagrumab
MD (fat mass) −4.72 kg(−8.05 to −1.40)
Bimagrumab
MD (total lean mass) 1.66 kg(0.81–2.51)
Each group vs placeboMD (HbA1c), % (95% CI)
Bimagrumab
−0.13(−0.23 to −0.03)

Safety

OutcomeIncrease (mmol/L) (CI)
LDL concentration0.47 (0.03–0.91)
OutcomeEstimate
Discontinuation, muscle spasms, diarrhoeaBimagrumabvs PlaceboRR (discontinuation) 5.75 (CI 1.61–20.46)
Discontinuation, muscle spasms, diarrhoeaBimagrumabvs PlaceboRR (muscle spasms) 10.44 (CI 4.23–25.75)
Discontinuation, muscle spasms, diarrhoeaBimagrumabvs PlaceboRR (diarrhoea) 4.91 (CI 2.38–10.11)

Original publication

Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Diabetes Obes Metab. Published 30 July 2026. doi:10.1111/dom.71156

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.